Pembrolizumab plus best supportive care versus placebo plus best supportive care as second-line therapy in patients in Asia with advanced hepatocellular carcinoma (HCC): Phase 3 KEYNOTE-394 study.

Shukui Qin, Chunyi Hao, Zhenggang Ren et al.|Journal of Clinical Oncology|2022

Cited by 111